Update on the therapy of adult-onset Still’s disease with a focus on IL-1-inhibition: a systematic review

1. Jamilloux, Y, Gerfaud-Valentin, M, Martinon, F, et al. Pathogenesis of adult-onset Still’s disease: new insights from the juvenile counterpart. Immunol Res 2015; 61: 53–62.
Google Scholar | Crossref | Medline2. Nirmala, N, Brachat, A, Feist, E, et al. Gene-expression analysis of adult-onset Still’s disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity. Pediatr Rheumatol Online J 2015; 13: 50.
Google Scholar | Crossref | Medline3. Jamilloux, Y, Gerfaud-Valentin, M, Henry, T, et al. Treatment of adult-onset Still’s disease: a review. Ther Clin Risk Manag 2015; 11: 33–43.
Google Scholar | Medline4. Laskari, K, Tektonidou, MG, Katsiari, C, et al. Outcome of refractory to conventional and/or biologic treatment adult Still’s disease following canakinumab treatment: countrywide data in 50 patients. Semin Arthritis Rheum 2021; 51: 137–143.
Google Scholar | Crossref | Medline5. Vitale, A, Berlengiero, V, Sota, J, et al. Real-life data on the efficacy of canakinumab in patients with adult-onset Still’s disease. Mediators Inflamm 2020; 2020: 8054961.
Google Scholar | Crossref | Medline6. Tomelleri, A, Campochiaro, C, De Luca, G, et al. FRI0506 efficacy and safety of canakinumab in adult-onset Still’s disease: a single-center real-life experience. J Ann Rheum Dis 2020; 79: 851–852.
Google Scholar | Medline7. Cavalli, G, Tomelleri, A, De Luca, G, et al. Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease. Arthritis Res Ther 2019; 21: 54.
Google Scholar | Crossref | Medline8. Colafrancesco, S, Priori, R, Valesini, G, et al. Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset Still’s disease: a multicentre retrospective observational study. Front Pharmacol 2017; 8: 369.
Google Scholar | Crossref | Medline9. Ugurlu, SGG, Yurttas, B, Ergezen, B, et al. Canakinumab treatment in adult-onset Still’s disease: case series [Abstract]. Arthritis Rheumatol 2018; 70(Suppl. 10), https://acrabstracts.org/abstract/canakinumab-treatment-in-adult-onset-stills-disease-case-series/
Google Scholar10. Vitale, A, Insalaco, A, Sfriso, P, et al. A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study. Front Pharmacol 2016; 7: 380.
Google Scholar | Crossref | Medline11. Kedor, C, Listing, J, Zernicke, J, et al. Canakinumab for treatment of adult-onset Still’s disease to achieve reduction of arthritic manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. Ann Rheum Dis 2020; 79: 1090–1097.
Google Scholar | Crossref | Medline12. Bodard, Q, Langlois, V, Guilpain, P, et al. Cardiac involvement in adult-onset Still’s disease: manifestations, treatments and outcomes in a retrospective study of 28 patients. J Autoimmun 2021; 116: 102541.
Google Scholar | Crossref | Medline13. Campochiaro, C, Farina, N, Tomelleri, A, et al. Drug retention rates of biological agents in adult onset Still’s disease. Semin Arthritis Rheum 2021; 51: 1–6.
Google Scholar | Crossref | Medline14. Schanberg, LNP, Cooper, A, Chatham, W, et al. A randomized, double-blind, placebo-controlled study of anakinra in pediatric and adult patients with Still’s disease [Abstract]. Arthritis Rheumatol 2020; 72(Suppl. 10), https://acrabstracts.org/abstract/a-randomized-double-blind-placebo-controlled-study-of-anakinra-in-pediatric-and-adult-patients-with-stills-disease-2/
Google Scholar15. Sfriso, P, Priori, R, Valesini, G, et al. Adult-onset Still’s disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. Clin Rheumatol 2016; 35: 1683–1689.
Google Scholar | Crossref | Medline16. Dall’Ara, F, Frassi, M, Tincani, A, et al. A retrospective study of patients with adult-onset Still’s disease: is pericarditis a possible predictor for biological disease-modifying anti-rheumatic drugs need? Clin Rheumatol 2016; 35: 2117–2123.
Google Scholar | Crossref | Medline17. Gao, X, Petryna, O. Clinical utility of MBDA panel in the management of adult onset Still’s disease. Mediterr J Rheumatol 2017; 28: 157–160.
Google Scholar | Crossref | Medline18. Castañeda, S, Atienza-Mateo, B, Martín-Varillas, JL, et al. Anakinra for the treatment of adult-onset Still’s disease. Expert Rev Clin Immunol 2018; 14: 979–992.
Google Scholar | Crossref | Medline19. Ruscitti, P, Cipriani, P, Masedu, F, et al. Adult-onset Still’s disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. BMC Med 2016; 14: 194.
Google Scholar | Crossref | Medline20. Chalasani, S, Majithia, V, Kishore, S. Doubling down on anakinra: a case of relapsing Still’s disease. J Investig Med 2018; 66: 384.
Google Scholar21. Vercruysse, F, Barnetche, T, Lazaro, E, et al. Adult-onset Still’s disease biological treatment strategy may depend on the phenotypic dichotomy. Arthritis Res Ther 2019; 21: 53.
Google Scholar | Crossref | Medline22. Kougkas, N, Avgustidis, N, Pitsigavdaki, S, et al. Biologics in adult’s onset Still’s disease: treatment strategies and safety in single center cohort with long-term follow-up, https://ard.bmj.com/content/79/Suppl_1/1811.1.abstract
Google Scholar23. Yazici, A, Dalkiliç, E, Birlik, M, et al. SAT0544 use of biological DMARDs in patients with adult-onset Still’s disease: results from TURKBIO registry. J Ann Rheum Dis 2020; 79: 1229–1229.
Google Scholar24. Marketos, N, Patelli, A, Papadopoulou-Marketou, N, et al. Anakinra for adult-onset Still’s disease despite old age. J Clin Rheumatol. Epub ahead of print 14 August 2020. DOI: 10.1097/rhu.0000000000001534.
Google Scholar | Crossref | Medline25. Sota, J, Rigante, D, Ruscitti, P, et al. Anakinra drug retention rate and predictive factors of long-term response in systemic juvenile idiopathic arthritis and adult onset Still disease. Front Pharmacol 2019; 10: 918.
Google Scholar | Crossref | Medline26. Summary of product characteristics, canakinumab-Ilaris , www.ema-europa.eu
Google Scholar27. Campochiaro, CTA, Giacomo, D, Farina, N, et al. Efficacy of canakinumab treatment in adult-onset Still’s disease [Abstract]. Arthritis Rheumatol 2019; 71(Suppl. 10), https://acrabstracts.org/abstract/efficacy-of-canakinumab-treatment-in-adult-onset-stills-disease/
Google Scholar28. Gabay, C, Fautrel, B, Rech, J, et al. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease. Ann Rheum Dis 2018; 77: 840–847.
Google Scholar | Medline29. Kiltz, U, Kiefer, D, Braun, J, et al. Prolonged treatment with tadekinig alfa in adult-onset Still’s disease. Ann Rheum Dis 2020; 79: e10.
Google Scholar | Crossref | Medline30. Vastert, SJ, Jamilloux, Y, Quartier, P, et al. Anakinra in children and adults with Still’s disease. Rheumatology 2019; 58: vi9–vi22.
Google Scholar | Crossref31. Vastert, SJ, de Jager, W, Noordman, BJ, et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol 2014; 66: 1034–1043.
Google Scholar | Crossref | Medline32. Feist, E, Mitrovic, S, Fautrel, B. Mechanisms, biomarkers and targets for adult-onset Still’s disease. Nat Rev Rheumatol 2018; 14: 603–618.
Google Scholar | Crossref | Medline33. Castañeda, S, Martínez-Quintanilla, D, Martín-Varillas, JL, et al. Tocilizumab for the treatment of adult-onset Still’s disease. Expert Opin Biol Ther 2019; 19: 273–286.
Google Scholar | Crossref | Medline34. Kaneko, Y, Kameda, H, Ikeda, K, et al. Tocilizumab in patients with adult-onset Still’s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis 2018; 77: 1720–1729.
Google Scholar | Crossref | Medline

留言 (0)

沒有登入
gif